Natera Inc (NASDAQ:NTRA) has received an average recommendation of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $29.00.
A number of analysts recently weighed in on NTRA shares. BidaskClub downgraded Natera from a “sell” rating to a “strong sell” rating in a report on Tuesday, November 13th. ValuEngine downgraded Natera from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 9th. Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. Finally, Cowen restated a “buy” rating and issued a $30.00 price objective on shares of Natera in a report on Friday, November 9th.
Shares of NASDAQ:NTRA traded up $0.17 during trading on Friday, hitting $15.39. 5,512 shares of the company were exchanged, compared to its average volume of 617,966. The company has a market capitalization of $911.90 million, a PE ratio of -6.33 and a beta of 1.79. The company has a debt-to-equity ratio of 1.30, a quick ratio of 2.32 and a current ratio of 2.44. Natera has a 1-year low of $8.60 and a 1-year high of $29.62.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
See Also: What is systematic risk?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.